Ryan Smith to present at the 8th Aging Research & Drug Discovery Meeting 2021

Thursday, July 8, 2021, 2PM London — Ryan Smith, Cofounder of TruDiagnostic, will present the latest research on the topic Longitudinal Epigenetic Methylation Signatures of Covid-19 and the most up to date data on the DunedIn Pace of Aging Methylation Clock, at the worlds’ largest annual Aging Research and Drug Discovery conference (8th ARDD).

Ryan Smith is the cofounder of TruDiagnostic. TruDiagnostic is a CLIA certified lab and health data company focused on serving integrative and functional medicine providers in the United States. Founded in 2020, TruDiagnostic has over 21 approved IRB research studies investigating the epigenetic methylation changes of a variety of longevity and health interventions. Since Tru Diagnostics inception, they have created one of the largest private epigenetic health databases in the world with over 13,000 patients tested. Through this data, TruDiagnostic has been able to add insight into the conversations of healthy aging and longevity.

In his lecture, Ryan Smith will review TruDiagnostics’ collaborations with academic institutions such as Cornell University and Duke University. This will include a review of the DunedinPoAm rate of aging clock and its application for clinical use and drug discovery. The DunedinPoAM algorithm is one of the most innovative and exciting aging clocks to date as it provides an instantaneous rate of aging rather than an overall age.

Ryan will also discuss the preliminary results of a research collaboration with Cornell university. With the help of immunology researchers at Cornell, TruDiagnostic has assessed the longitudinal epigenetic changes of patients before and after documented COVID-19 infection and the epigenetic changes associated with the mRNA based COVID Vaccines. The measurable differences of these longitudinal changes give insight into post covid syndromes and give us an epigenetic signature tied to covid-19 exposure which is more sensitive than anything currently published to date.

Ryan Smith attended Transylvania University and graduated with a degree in Biochemistry. In that time, he had multiple research internships at the University of Kentucky and the University of Pennsylvania studying large scale protein synthesis and physical chemistry. After graduation, he attended medical school at the University of Kentucky for 2 years. After finishing all the educational curriculum and passing USMLE Step 1 he decided to leave and help open up a pharmacy in the United States that focused on peptide synthesis and formulations for pharmaceutical preparations. Since that time, Tailor Made Compounding has become the 4th fastest growing company in healthcare and 21st fastest growing business in the US. Tailor Made Compounding was the first pharmacy to offer an extensive list of peptides in the US and continues research and expansion for the use of these products for the integrative medicine space. Since then, Ryan has opened many businesses including TruDiagnostic, a company focusing on methylation array-based diagnostics for life extension and preventive healthcare.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at http://www.agingpharma.org. Please review the conference proceedings for 2019 and 2020.

“Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2021 conference is the best yet with top level speakers from around the globe. I’m extremely excited to be able to meet them in person at the University of Copenhagen in late summer.”, said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place online and was a great success. This year’s event will be a hybrid meeting with virtual and in-person attendees. I am particularly excited that being part of the ARDD 2021 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field.” said Daniela Bakula, Ph.D., University of Copenhagen

“Aging research is gaining traction in the biopharmaceutical industry. To my knowledge, 6 out of the top 30 pharmaceutical companies in the world prioritized aging research for early-stage discovery or therapeutic pipeline development and several companies employ artificial intelligence for this purpose. We organize the annual ARDD conference for eight years in a row and the level of interest in aging biomarkers and noticed exponential growth in registrations over the past two years”, said Alex Zhavoronkov, Ph.D., co-founder and CEO of Insilico Medicine, and the founder of Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the “Longevity Medicine” course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.

###

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), whose shares are listed on the Hong Kong Stock Exchange. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://deeplongevity.com/

Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com/

TruDiagnostic is a leading health data company with a focus on multiomics and insights gained from the fluid epigenome. Established in early 2020, after development and build out of its 10,000 sq ft state of the art laboratory with Illumina equipment and consultation it launched its first physician and patient test “TruAge”. Today, Tru has built a premiere epigenetic database of DNA Methylation markers and covariates which is one of the largest in the world. The company is currently involved in several clinical studies to examine the effectiveness of products that claim to offer anti-aging benefits, and research projects to create and validate other algorithms to track aging and disease.